These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29802086)

  • 1. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation.
    Asleh R; Prasad M; Briasoulis A; Nardi V; Adigun R; Edwards BS; Pereira NL; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Sep; 37(9):1083-1092. PubMed ID: 29802086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
    J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.
    Topilsky Y; Hasin T; Raichlin E; Boilson BA; Schirger JA; Pereira NL; Edwards BS; Clavell AL; Rodeheffer RJ; Frantz RP; Maltais S; Park SJ; Daly RC; Lerman A; Kushwaha SS
    Circulation; 2012 Feb; 125(5):708-20. PubMed ID: 22207715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
    JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression.
    Raichlin E; Bae JH; Kushwaha SS; Lennon RJ; Prasad A; Rihal CS; Lerman A
    J Am Coll Cardiol; 2009 Apr; 53(15):1279-86. PubMed ID: 19358941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.
    Potena L; Fearon WF; Sydow K; Holweg C; Luikart H; Chin C; Weisshaar D; Mocarski ES; Lewis DB; Valantine HA; Cooke JP
    Transplantation; 2008 Mar; 85(6):827-33. PubMed ID: 18360263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients.
    Ozcan I; Toya T; Corban MT; Ahmad A; Loeffler D; Morse D; Lerman LO; Kushwaha SS; Lerman A
    Cardiovasc Res; 2022 Jun; 118(7):1703-1712. PubMed ID: 34132771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients.
    Kittleson MM; Bead V; Fradley M; St John ME; Champion HC; Kasper EK; Russell SD; Wittstein IS; Hare JM
    J Heart Lung Transplant; 2007 May; 26(5):498-503. PubMed ID: 17449420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive aortic pulse pressure is linked to cardiac allograft vasculopathy after heart transplantation.
    Park HW; Ozcan I; Toya T; Ahmad A; Kanaji Y; Kushwaha SS; Lerman LO; Lerman A
    Int J Cardiol; 2023 Jan; 370():167-174. PubMed ID: 36346255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
    Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Layered Fibrotic Plaques Are the Predominant Component in Cardiac Allograft Vasculopathy: Systematic Findings and Risk Stratification by OCT.
    Clemmensen TS; Holm NR; Eiskjær H; Løgstrup BB; Christiansen EH; Dijkstra J; Barkholt TØ; Terkelsen CJ; Maeng M; Poulsen SH
    JACC Cardiovasc Imaging; 2017 Jul; 10(7):773-784. PubMed ID: 28330670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study.
    Chih S; Chong AY; Džavík V; So DY; Aleksova N; Wells GA; Bernick J; Overgaard CB; Stadnick E; Mielniczuk LM; Beanlands RSB; Ross HJ
    Circ Heart Fail; 2023 Jun; 16(6):e010173. PubMed ID: 37165901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated-Signal Plaque Progression Predicts Long-Term Mortality After Heart Transplantation: IVUS Assessment of Cardiac Allograft Vasculopathy.
    Okada K; Fearon WF; Luikart H; Kitahara H; Otagiri K; Tanaka S; Kimura T; Yock PG; Fitzgerald PJ; Yeung AC; Valantine HA; Khush KK; Honda Y
    J Am Coll Cardiol; 2016 Jul; 68(4):382-92. PubMed ID: 27443435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
    Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation.
    Asleh R; Briasoulis A; Smith B; Lopez C; Alnsasra H; Pereira NL; Edwards BS; Clavell AL; Stulak JM; Locker C; Kremers WK; Daly RC; Lerman A; Kushwaha SS
    J Card Fail; 2021 May; 27(5):542-551. PubMed ID: 33962742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of Rapidly Progressive Cardiac Allograft Vasculopathy Using mTOR Inhibition After Heart Transplantation.
    Sperry BW; Zein RE; Fendler TJ; Sauer AJ; Khumri TM; Magalski A; Austin BA; Safley D; Kao AC
    J Card Fail; 2024 Apr; 30(4):613-617. PubMed ID: 37992800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Study of Pediatric Coronary Allograft Vasculopathy Between Single Centers in North America and United Kingdom.
    Fenton M; Mahmood A; Burch M; Simmonds J; Kuhn MA
    Transplant Proc; 2018 Dec; 50(10):3705-3709. PubMed ID: 30577259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice.
    Masetti M; Potena L; Nardozza M; Prestinenzi P; Taglieri N; Saia F; Pece V; Magnani G; Fallani F; Coccolo F; Russo A; Rapezzi C; Grigioni F; Branzi A
    Am J Transplant; 2013 May; 13(5):1217-26. PubMed ID: 23621161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.